European Journal of Cancer Supplements, 1359-6349

Tidskrift

Fler filtreringsmöjligheter
Fler filtreringsmöjligheter

Alla författare

Återställ
till
11 - 20 av 27Sidstorlek: 10

  1. Cyclin A - an alternative to gene expression profiling for subdividing histological grade 2 breast cancer into groups with different prognosis

    Carina Forsare, Anette AhlinGullers, M. L. Fjallskog, P. Malmstrom & Mårten Fernö, 2010, I: EJC Supplements. 8, 3, s. 95-96

    Forskningsoutput: Tidskriftsbidrag › Publicerat konferensabstract

  2. Lactoferricin treatment delays cell cycle progression of a human colon cancer cell line

    Catja Freiburghaus, Helena Lindmark Månsson, Stina Oredsson & Marie Paulsson, 2008, I: EJC Supplements. 6, 9, s. 150-150

    Forskningsoutput: Tidskriftsbidrag › Publicerat konferensabstract

  4. Interim analysis of epidermal-growth factor receptor (EGFR) expression in a single-arm, phase II, first-line study (20060314) of panitumumab with FOLFIRI in the management of metastatic colorectal cancer (mCRC)

    C. Koehne, R. Hofheinz, L. Mineur, H. Letocha, R. Greil, J. Thaler, E. Gamelin, Eva Fernebro, L. Wright & M. Karthaus, 2009, I: EJC Supplements. 7, 2, s. 343-344

    Forskningsoutput: Tidskriftsbidrag › Publicerat konferensabstract

  5. Prognostic value of gene expression targeted by gain of 17q sequences in malignant peripheral nerve sheath tumours

    M. Kolberg, T. H. Agesen, M. Holand, H. R. Brekke, R. I. Skotheim, K. S. Hall, E. van den Berg, Fredrik Mertens, S. Smeland & R. A. Lothe, 2010, I: EJC Supplements. 8, 5, s. 122

    Forskningsoutput: Tidskriftsbidrag › Publicerat konferensabstract

  6. A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer

    S Margolin, L Carlsson, M Hellström, P Karlsson, E Lidbrink, B Linderholm, H Lindman, Per Malmström, D Sköld Pettersson & J Bergh, 2008, I: European Journal of Cancer Supplements. 6, 7, s. 116-117

    Forskningsoutput: Tidskriftsbidrag › Publicerat konferensabstract

  7. Pattern of use of second-line treatment for NSCLC in the Nordic countries

    A. Mellemgaard, Lars Ek, H. Riska & R. Tell, 2009, I: EJC Supplements. 7, 2, s. 527-527

    Forskningsoutput: Tidskriftsbidrag › Publicerat konferensabstract

  8. Ki-67 as a long-term prognostic factor in lobular breast cancer

    Ulrik Narbe, Pär-Ola Bendahl, Dorthe Grabau, Lisa Rydén, Mårten Fernö & Christian Ingvar, 2010, I: EJC Supplements. 8, 3, s. 98-98

    Forskningsoutput: Tidskriftsbidrag › Publicerat konferensabstract

  9. E28. Breast tolerance, tibolone compared to other hormonal treatments

    Hakan L. Olsson, 2004 dec, I: European Journal of Cancer, Supplement. 2, 9 SPEC. ISS., s. 79-80 2 s.

    Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift

  10. Systematic validation of novel breast cancer progression-associated biomarkers via high-throughput antibody generation and application of tissue microarray technology

    S A Penny, C M Kelly, D J Brennan, A C Culhane, D G Higgins, P A Dervan, Karin Jirström, F Ponten, M Uhlen & W M Gallagher, 2008, I: European Journal of Cancer Supplements. 6, 7, s. 59-59

    Forskningsoutput: Tidskriftsbidrag › Publicerat konferensabstract

Föregående 1 2 3 Nästa